Mitchell Seyedin, Ph.D., joined ISTO in September 2003 and served as its president and CEO through 2013. Prior to joining ISTO Technologies, Dr. Seyedin was President and CEO of CBYON Inc., a developer and marketer of advanced image-guided surgical systems. In 1995, he founded Orquest, an orthobiologics company that developed biological products for orthopedic applications. He served as Orquest's CEO through 1997, as Chairman through 2001 and as a Board member until its acquisition by Johnson & Johnson in 2003. In 1990, Dr. Seyedin co-founded Metra Biosystems and served as Vice President of Research & Development. In 1995, Metra completed a public offering and was then acquired by Quidel (NASDAQ:QDEL) in June 1999. Before founding Metra, Dr. Seyedin was the Director of Research at Collagen Corporation, where he oversaw responsibility for bone and cartilage research. Dr. Seyedin holds a B.S. in Chemistry from the University of Wisconsin, a Ph.D. in Biochemistry from the University of South Carolina and completed his post-doctoral training at the University of California - Berkeley.
George Dunbar joined ISTO in January 2014. Prior to joining ISTO, Mr. Dunbar was a Venture Partner with Arboretum Ventures. Mr. Dunbar has extensive healthcare operating experience as a former senior executive with a number of venture-backed healthcare companies in the areas of diagnostics, life science tools, and medical devices. Prior to joining Arboretum, Mr. Dunbar was the President, CEO, and Chairman of Aastrom Biosciences (NASDAQ: ASTM), a clinical development stage healthcare company based in Ann Arbor, Michigan. Prior to Aastrom, Mr. Dunbar worked with several national venture capital firms, serving as the CEO of early-stage life science companies, including Quantum Dot (acquired by Invitrogen) and Epic Therapeutics (acquired by Baxter Healthcare). He has also held senior positions in licensing, business development and marketing with the Areas-Serono Group and Amersham International. Mr. Dunbar received a B.S. in Electrical Engineering from Auburn University and a Masters in Business Administration from Auburn University.
Scott Gill joined ISTO Technologies in December 2007 with 15 years of investment banking and corporate finance experience. Prior to joining the Company, Mr. Gill was a Director with the Investment Banking group of A.G. Edwards & Sons, Inc. where he worked with a number of public and private emerging growth companies on a variety of corporate finance advisory assignments with a particular emphasis on M&A transactions for clients in the healthcare sector. Before joining A.G. Edwards, Mr. Gill was a Senior Financial Analyst with Anheuser-Busch, Inc. and a commercial banker with Bank of America. Mr. Gill received his Bachelor of Arts in economics from the University of Tennessee and his Master of Business Administration from the J.L. Kellogg School of Management at Northwestern University.
Phillip Kuhn joined ISTO in April 2014 with over 30 years of medical device and biologics marketing and sales experience, having successfully launched both new products and businesses in a variety of sectors. Prior to joining the Company, Mr. Kuhn was Vice President US Marketing at Orthofix International N.V. where he was responsible for their orthopedic products group. Prior to Orthofix, Mr. Kuhn was the Vice President of Strategic Marketing for the Biologics division of Smith and Nephew where he led their OA/Cartilage programs. In addition, he was responsible for the introduction of the division's first new product launch. Before joining Smith & Nephew, Mr. Kuhn held positions of increasing responsibility with Boston Scientific, where he eventually led their global peripheral stent group. Mr. Kuhn's experience also includes marketing and sales leadership positions with: Ethicon Endosurgery and Indigo Medical, a new start-up which Mr. Kuhn helped establish, both Johnson & Johnson Companies; Baxter International; and Abbott Laboratories. Mr. Kuhn received his Bachelor of Arts from Duke University and his Master of Business Administration from the Goizueta School at Emory University.
Penny White joined ISTO in May 2000 with 16 years of experience in the biopharmaceutical industry including serving as the Associate Director of Regulatory Affairs for Chiron Corporation, and prior to that as the Associate Director of Technical Affairs for Centocor, Inc. During that time she prepared numerous documents for submission to regulatory bodies, both U.S. and foreign, with successful outcomes leading to product approvals. She is a member of the Regulatory Affairs Professional Society with certification as a Regulatory Affairs Professional, and has a B.S. in Biology from Texas A&M University.
Michaela Purcell joined ISTO in 2007. She has more than 25 years of experience in leading the strategic planning and clinical execution of multiple research programs involving orthopedic and gastrointestinal devices, MRI imaging, and pharmaceutical and biologic products in Europe, Latin America and the United States. Prior to joining ISTO, she was an independent clinical operations consultant with primary responsibilities for the clinical development of translational research. She was founder and director of two Site Management Organizations with responsibilities for recruiting, training and oversight of research management personnel. Prior to that time, she was a senior Scientific Liaison for Eli Lilly and Company in the fields of Neurosciences, Urology and Gynecology with responsibilities for investigator selection, educational and research grant management, training of field medical personnel, and medical communications compliance. Ms. Purcell served for 12 years as a clinical specialist in research and medical education at St. Louis University School of Medicine with responsibilities in adult and pediatric outpatient services, grant procurement and publication strategy. Ms. Purcell holds a BSN from Vanderbilt University and an MSN in Education and Research from St. Louis University.